{"DataElement":{"publicId":"3104394","version":"1","preferredName":"Patient Chemotherapy Eligibility Determination Ind-4","preferredDefinition":"the indicator related to patient determination of eligibility in reference to use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"3104392v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3104392","version":"1","preferredName":"Patient Chemotherapy Eligibility Determination","preferredDefinition":"information related to patient determination of eligibility in reference to use of synthetic or naturally-occurring chemicals for the treatment of diseases.","longName":"2233604v1.0:3104390v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3104390","version":"1","preferredName":"Chemotherapy Eligibility Determination","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C15632:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FBD7AF-FF5B-BBC7-E040-BB89AD43112A","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCIC CRF:National Cancer Institute of Canada Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87FBD7AF-FF6C-BBC7-E040-BB89AD43112A","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506035","version":"1","preferredName":"Yes No Unknown Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"YES_NO_UNKNOWN_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D41-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D4B-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D55-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D5F-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694968","version":"1","preferredName":"Ind-4","preferredDefinition":"A response or indicator that can have a value of yes, no, unknown, or not applicable.","longName":"C49486","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, Unknown, or Not Applicable Response","conceptCode":"C49486","definition":"A response or indicator that can have a value of yes, no, unknown, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCAFD6-ECF0-4640-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 requested By Tina Taylor approved by Dianne Reeves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C379D9D0-6D2D-CCDD-E040-BB89AD432590","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"COOPERM","dateModified":"2020-08-13","changeDescription":"3/12/17 jk added Standard reg status; ownership  transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 3/23/16 jk value \"Not evaluable\" added in error by COG on 3/21/16 was removed.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104895","version":"1","longName":"GOG-0238","context":"NRG"},{"publicId":"4104996","version":"1","longName":"GOG-0279","context":"NRG"},{"publicId":"4471913","version":"1","longName":"NRG-CC002","context":"NRG"},{"publicId":"10000043","version":"1","longName":"NRG-CC002","context":"NRG"},{"publicId":"4514847","version":"1","longName":"NRG-CC002","context":"NRG"},{"publicId":"4104991","version":"1","longName":"GOG-0275","context":"NRG"}]},{"publicId":"6147165","version":"1","longName":"Wake Forest Baptist Medical Center","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6147167","version":"1","longName":"WFB","context":"NCIP"}]}],"AlternateNames":[{"name":"PtChxEligDtmnIND","type":"COG GDE Short Name","context":"CTEP"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"3104392v1.0:2018257v1.0","type":"USED_BY","context":"NRG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"3104392v1.0:2018257v1.0","type":"USED_BY","context":"CITN"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PT_CHEMO_ELG_DTMN_IND","type":"Context Short Name","context":"NRG"},{"name":"CHEMTX_ELIG_IND","type":"OID, CCTG","context":"CCTG"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"3104392v1.0:2018257v1.0","type":"USED_BY","context":"CCTG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"NCIP","type":"USED_BY","context":"NCIP"},{"name":"IE_IEORRES_CHEMTX","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Chemotherapy, if given, has b","type":"Preferred Question Text","description":"Chemotherapy, if given, has been completed at least 4 weeks prior to randomization","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Has the patient received Prior Treatment with cytotoxic chemotherapy","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Has the patient received Prior Treatment with cytotoxic chemotherapy for the current diagnosis of ALL or any cancer diagnosed previously","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"If so, was the therapy completed at least 6 months prior to today's date and is there clear evidence of disease subsequent to such therapy?","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Has the patient previously been treated with cytotoxic chemotherapy?","url":null,"context":"CTEP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Prior chemotherapy or small molecule inhibitors if >=4 weeks since completion prior to registration","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Greater than or equal to 4 weeks from prior chemotherapy, small molecule cell cycle inhibitors or other investigational agents (>=6 weeks from nitrosoureas) at the time of registration","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has the patient previously been treated with pelvic radiation or cytotoxic chemotherapy?","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Is the patient on or will they be on a chemotherapy regimen for a duration of  greater than or equal to 3 months?","url":null,"context":"CTEP"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"At least 4 weeks from last dose of prior chemotherapy or non-antibody immunomodulator therapy with resolution of the acute toxic effects of the therapy. For patients coming off of BRAF inhibitor (e.g., IL-2) or other molecularly targeted therapy, at least 2 weeks since last dose and full recovery from toxicities","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is the patient on or will be on a chemotherapy regimen for a duration of  greater than or equal to 3 months or is on or will be on a chemotherapy regimen for less than 3 months and then proceed to transplant during the study period?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Has the patient received chemotherapy treatment (for a gynecologic malignancy) prior to consideration of enrollment into this trial and taking the geriatric assessment?","url":null,"context":"NRG"},{"name":"CITN","type":"Alternate Question Text","description":"At least 4 weeks from last dose of prior chemotherapy or immunomodulator therapy with resolution of the acute toxicities. For patients coming off molecularly-targeted therapy, at least 2 weeks since last dose and recovery from laboratory and constitutional toxicities. Patients must meet entry eligibility criteria.","url":null,"context":"CITN"},{"name":"EAI142 Text","type":"Alternate Question Text","description":"Does the patient have a history of greater than 1 line of administered chemotherapy for metastatic disease and been off chemotherapy for a minimum of 2 weeks?  Prior chemotherapy in the adjuvant setting is allowed.","url":null,"context":"ECOG-ACRIN"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Was anthracycline or anthraquinone, aside from doxorubicin, ever given as part of initial or subsequent therapies?","url":null,"context":"COG"},{"name":"CRF_NRG_ELIG","type":"Alternate Question Text","description":"Has the patient received 3-6 months of gemcitabine/cisplatin chemotherapy?","url":null,"context":"NRG"},{"name":"CRF_TEXT_12","type":"Alternate Question Text","description":"Has the patient received systemic chemotherapy for the study cancer less than 2 weeks prior to registration?","url":null,"context":"NRG"},{"name":"NRG CRF_Text1","type":"Alternate Question Text","description":"Is there planned use of cytotoxic chemotherapy during radiation?","url":null,"context":"NRG"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Has the patient received treatment with any other investigational agent within 4 weeks prior to randomization?","url":null,"context":"CTEP"},{"name":"CE7","type":"Alternate Question Text","description":"Is there a plan for the patient to receive cytotoxic chemotherapy within 48 hours prior or after the SRS or WBRT?","url":null,"context":"CCTG"},{"name":"COG_CRF_Text_4","type":"Alternate Question Text","description":"Has patient completed curative chemotherapy within past 6 months at a COG institution?","url":null,"context":"COG"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Has the patient completed prior cytotoxic chemotherapy at least 28 days prior to registration?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text_2","type":"Alternate Question Text","description":"Has the patient participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_1","type":"Alternate Question Text","description":"Was prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) completed equal or greater than 12 months prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Was prior adjuvant chemotherapy (e.g., paclitaxel/carboplatin alone or as a component of concurrent chemotherapy and radiation therapy [with or without cisplatin]) completed equal or greater than 12 months prior to Step 1 registration?","url":null,"context":"NRG"},{"name":"CRF Text 10","type":"Alternate Question Text","description":"Did the patient complete appropriate institutional neoadjuvant chemotherapy?","url":null,"context":"CTEP"},{"name":"CRF Text13","type":"Alternate Question Text","description":"was last day of chemotherapy > 21 days prior to registration?","url":null,"context":"Alliance"},{"name":"WF-97415","type":"Alternate Question Text","description":"Scheduled to receive chemotherapy","url":null,"context":"NCIP"},{"name":"WF-1806","type":"Alternate Question Text","description":"Planning to undergo 1st line 5-FU based chemotherapy (as monotherapy [as 5-FU alone or capecitabine] or in combination with oxaliplatin and/or irinotecan +/- biologics).","url":null,"context":"NCIP"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Has the patient had any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer?","url":null,"context":"NRG"},{"name":"CRF Text12","type":"Alternate Question Text","description":"was last day of chemotherapy greater than 21 days prior to registration?","url":null,"context":"Alliance"},{"name":"CRF Text11","type":"Alternate Question Text","description":"was last day of chemotherapy >= 21 days prior to registration?","url":null,"context":"Alliance"},{"name":"COG CRF TEXT 5","type":"Alternate Question Text","description":"Has patient completed curative therapy (surgery and/or radiation and/or chemotherapy) within past 6 months at a COG institution?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_5","type":"Alternate Question Text","description":"Did the prior chemotherapy include a first line platinum based regimen with or without consolidation chemotherapy?","url":null,"context":"NRG"},{"name":"EAI142_2","type":"Alternate Question Text","description":"Does the patient have a history of greater than 1 line of administered chemotherapy for metastatic disease?","url":null,"context":"ECOG-ACRIN"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Has patient completed all cancer treatment within 3 to 36 calendar months prior to enrollment?","url":null,"context":"COG"},{"name":"NRG_eCRF_Text_6","type":"Alternate Question Text","description":"Has the patient participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to Step 2 registration?","url":null,"context":"NRG"},{"name":"WF97415v2","type":"Alternate Question Text","description":"Scheduled to receive chemotherapy and/or estrogen antagonist aromatase inhibitors (anastrozole [Arimidex], letrozole [Femara], exemestane [Aromasin])","url":null,"context":"NCIP"},{"name":"NRG_eCRF_Text_7","type":"Alternate Question Text","description":"Has the patient had any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary colon adenocarcinomas for which treatment with neoadjuvant chemotherapy and/or radiation is warranted are not permitted)?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text_8","type":"Alternate Question Text","description":"Has the patient completed prior cytotoxic chemotherapy at least 28 days prior to Step 2 registration?","url":null,"context":"NRG"},{"name":"WF-106 Amendment","type":"Alternate Question Text","description":"Planning to undergo immunotherapy and/or 5-FU based chemotherapy as first line of treatment.  5-FU chemotherapy can be 5-FU along or in combination with oxaliplatin and/or irinotecan; +/- immunotherapy.  Capecitabine is also acceptable.","url":null,"context":"NCIP"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Participants receiving strong or moderate CYP3A inhibitors must agree to discontinue use at least 48 hours prior to start of study treatment.","url":null,"context":"CCTG"},{"name":"Alliance 1","type":"Alternate Question Text","description":"No more than 1 line of prior chemotherapy for metastatic or locally advanced disease (neoadjuvant or adjuvant chemotherapy will be allowed if given 12 or more months prior to registration).","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_9","type":"Alternate Question Text","description":"Has the last dose of chemotherapy been administered at least 3 weeks prior to registration (to ensure recovery from nadir period of previous line of therapy)?","url":null,"context":"NRG"},{"name":"Alliance - 1","type":"Alternate Question Text","description":"Received prior chemotherapy for B-cell ALL/LBL","url":null,"context":"Alliance"},{"name":"WF-1806 Text 1","type":"Alternate Question Text","description":"Planning to or recently started to undergo immunotherapy and/or 5-FU based on chemotherapy as first line of treatment.  5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan; plus or minus immunotherapy.  Capecitabine is also acceptable.  If unable to engage patient before treatment starts, enrollment is allowed up to four weeks after the start of treatment but must be before Cycle 2 begins.","url":null,"context":"NCIP"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Has patient received chemotherapy or treatment for a prior malignancy?","url":null,"context":"COG"},{"name":"Alliance 2","type":"Alternate Question Text","description":"No other chemotherapy regimen in locally advanced metastatic setting besides the first line chemotherapy","url":null,"context":"Alliance"}],"origin":"NCIC CRF:National Cancer Institute of Canada Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"87FBD7AF-FF7E-BBC7-E040-BB89AD43112A","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-01","modifiedBy":"ZHWENDY","dateModified":"2024-01-18","changeDescription":"Replaced VD Eligibility Ind-4 2774784v1 with VD ID#3506035 - Yes No Unknown Not Applicable Indicator - dbw","administrativeNotes":"2022.11.4 AQT added for ticket request CADSR0001656. ak","unresolvedIssues":null,"deletedIndicator":"No"}}